Literature DB >> 24903793

Primary drug resistance among pulmonary treatment-naïve tuberculosis patients in Amazonas State, Brazil.

M da Silva Garrido1, R Ramasawmy1, T M Perez-Porcuna1, E Zaranza2, A Chrusciak Talhari1, F E Martinez-Espinosa1, S Bührer-Sékula1.   

Abstract

BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is the main indicator of previous treatment in tuberculosis (TB) patients. MDR-TB among treatment-naïve patients indicates infection with drug-resistant Mycobacterium tuberculosis strains, and such cases are considered primary drug-resistant cases.
OBJECTIVE: To estimate the prevalence of drug resistance in pulmonary TB (PTB) treatment-naïve patients and to identify the socio-demographic and clinical characteristics of the resistant population.
METHODS: A total of 205 treatment-naïve PTB patients from Manaus, Amazonas State, Brazil, were enrolled. Drug susceptibility testing (DST) was performed on all positive mycobacterial cultures using the 1% proportion method.
RESULTS: Positive M. tuberculosis cultures were obtained from only 175 patients for DST. The prevalence of primary MDR-TB was 1.7% (3/175); 14.3% (25/175) of the cultures presented resistance to at least one of the drugs. Resistance to streptomycin, isoniazid, rifampicin and ethambutol was respectively 8.6%, 6.9%, 3.4% and 2.3%. An association between TB patients with resistance to more than one drug and known previous household contact with a TB patient was observed (P= 0.008, OR 6.7, 95%CI 1.2-67.3).
CONCLUSIONS: Although the prevalence of primary MDR-TB currently is relatively low, it may become a major public health problem if tailored treatment is not provided, as resistance to more than one drug is significantly associated with household contact.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24903793     DOI: 10.5588/ijtld.13.0191

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

1.  [Antituberculosis-drug resistance in the border of Brazil with Paraguay and Bolivia].

Authors:  Marli Marques; Eunice Atsuko Totumi Cunha; Maria do Socorro Nantua Evangelista; Paulo Cesar Basta; Ana Maria Campos Marques; Julio Croda; Sonia Maria Oliveira de Andrade
Journal:  Rev Panam Salud Publica       Date:  2017-04-20

2.  Primary bacillary resistance in multidrug-resistant tuberculosis and predictive factors associated with cure at a referral center in São Paulo, Brazil.

Authors:  Marcia Telma Guimarães Savioli; Nelson Morrone; Ilka Santoro
Journal:  J Bras Pneumol       Date:  2019-03-11       Impact factor: 2.624

3.  Differential yield of universal versus selective drug susceptibility testing of patients with tuberculosis in high-burden countries: a systematic review and meta-analysis.

Authors:  Anita Svadzian; Giorgia Sulis; Genevieve Gore; Madhukar Pai; Claudia M Denkinger
Journal:  BMJ Glob Health       Date:  2020-10

4.  Primary and acquired multidrug-resistant tuberculosis: Predictive factors for unfavorable treatment outcomes in Rio de Janeiro, 2000-2016.

Authors:  Marcela Bhering; Afrânio Kritski
Journal:  Rev Panam Salud Publica       Date:  2020-12-30

5.  Genetic diversity and molecular epidemiology of multidrug-resistant Mycobacterium tuberculosis in Minas Gerais State, Brazil.

Authors:  Nayanne Gama Teixeira Dantas; Phillip Noel Suffys; Wânia da Silva Carvalho; Harrison Magdinier Gomes; Isabela Neves de Almeida; Lida Jouca de Assis; Claudio José Augusto; Michel Kireopori Gomgnimbou; Guislaine Refregier; Christophe Sola; Silvana Spíndola de Miranda
Journal:  BMC Infect Dis       Date:  2015-08-01       Impact factor: 3.090

6.  Molecular characterization of pre-extensive drug resistant Mycobacterium tuberculosis in Northeast Brazil.

Authors:  Thales Alves Campelo; Luana Nepomuceno Costa Lima; Karla Valéria Batista Lima; Caroliny Soares Silva; Marília Lima da Conceição; José Antonio Pereira Barreto; Aquiles Paulino Peres Mota; Soraya de Oliveira Sancho; Cristiane Cunha Frota
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2020-02-07       Impact factor: 1.846

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.